immunosuppression

Novantrone Lowers Relapses, Eases Disability in Highly Active RRMS

Initial treatment with Novantrone (mitoxantrone) can reduce the risk of relapses and worsening disability in people with highly active relapsing-remitting multiple sclerosis (RRMS), according to a 10-year study from France. “Our results support the short-term use of [Novantrone], followed by a maintenance therapy for patients with early highly…

The Rise of Superbugs, Antibiotic Resistance, and MS

I am living with an unenviable reality. An antibiotic-resistant, hospital-acquired infection that I developed two decades ago has reappeared. Before my multiple sclerosis diagnosis, I had a spinal cord stimulator implanted for pain control. Although the stimulator was removed shortly afterward, the infection remained. This infection presents itself when…

Potential MS Treatment Targeting CD3 Receptor Moving into Development

Tiziana Life Sciences, plc, a biotechnology company specializing inĀ drugs to treat immunological and oncological diseases,Ā  recently announced its intentĀ toĀ further develop foralumab, a fully human monoclonal antibody targeting the CD3 receptor. This approach, aimingĀ to modulate the immune T cell response and achieve immunosuppression, is well-validated and has the potential to…